The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial
An erratum to this article was published (Osteoporos Int, Feb 2024 ↗)
Authors' conclusion
These results suggest that after one year of denosumab, one year of alendronate is better able to maintain the inhibition of bone remodeling and BMD gains than raloxifene.
Study context
- Population
- Postmenopausal women at increased risk of fracture
- Participants
- 51 women
- Comparison
- Denosumab for 12 months followed by alendronate vs followed by raloxifene for 12 months
Methodological detailsopen-label, comparative efficacy
- Open-label
- Comparative efficacy
Primary result
As reported in the abstract
BMD change after denosumab discontinuation
Denosumab-to-raloxifene: spine bone mineral density (BMD) decrease
2.0%
95% CI −3.2 to −0.8P = 0.003
Denosumab-to-raloxifene: total hip BMD decrease (−2.1 to −0.4%, P = 0.008)
1.2%
Further findings
Serum bone remodeling markers after denosumab discontinuation
- Remained suppressed with alendronate; gradually increased to baseline with raloxifene
Original publication
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporos Int. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →